LABORATORY RESEARCH Chloroquine Eliminates Cancer Stem Cells through Deregulation of Jak2 and DNMT1 Researchers report that chloroquine sensitizes triple negative breast cancer cells to paclitaxel through inhibition of autophagy and reduces the CD44+/CD24-/low cancer stem cell population in both preclinical and clinical settings. [Stem Cells] Abstract A Novel Oncogenic Role of Inositol Phosphatase SHIP2 in ER-Negative Breast Cancer Stem Cells: Involvement of JNK/Vimentin Activation Investigators showed that the percentage of SH2-containing-5′-inositol phosphatase-2 (SHIP2)+ cells was positively correlated with that of CD24–CD44+ cells in 60 breast cancer specimens. Among 20 estrogen receptor (ER)-negative samples, 17 had greater SHIP2 expression in CD24–CD44+ subpopulation than the remaining subpopulation. [Stem Cells] Abstract Bone Marrow Endothelium-Targeted Therapeutics for Metastatic Breast Cancer Researchers tested targeted delivery of therapeutic siRNA loaded in the E-selectin thioaptamer-conjugated multistage vector drug carrier to bone marrow for the treatment of breast cancer bone metastasis. [J Control Release] Abstract p38 MAPK Inhibits Breast Cancer Metastasis through Regulation of Stromal Expansion Researchers report that p38 activation in breast cancer cells inhibits tumor metastasis but does not substantially modulate primary tumor growth. Stable p38 knockdown in breast cancer cells suppressed NF-κB p65 activation, inhibiting miR-365 expression and resulting in increased IL-6 secretion. [Int J Cancer] Abstract 14-3-3Ï„ Promotes Breast Cancer Invasion and Metastasis by Inhibiting RhoGDIα Investigators identify a critical role for 14-3-3Ï„ in promoting breast cancer metastasis, in part through binding to and inhibition of RhoGDIα, a negative regulator of Rho GTPases and metastasis suppressor. [Mol Cell Biol] Abstract Mesenchymal Stem Cells Inhibit Breast Cancer Cell Migration and Invasion through Secretion of Tissue Inhibitor of Metalloproteinase-1 and -2 Scientists describe a mechanism by which mesenchymal stem cells may be anti-tumorigenic, through inhibition of breast cancer cell migration and invasion, an important part of metastasis. [Mol Carcinog] Abstract CLINICAL RESEARCH Systemic Therapy for Patients with Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline The authors aimed to provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2-positive advanced breast cancer. [J Clin Oncol] Abstract Two Histopathologically Different Diseases: Hormone Receptor-Positive and Hormone Receptor-Negative Tumors in HER2-Positive Breast Cancer The authors investigated various histopathologic features of human epidermal growth factor 2 (HER2)-positive breast cancer and their correlation with hormone receptor status. They retrospectively analyzed tumors of 450 HER2-positive breast cancer patients treated with chemotherapy and one year of trastuzumab. [Breast Cancer Res Treat] Abstract |